Long-acting muscarinic antagonists (LAMAs), as add-on therapy to inhaled corticosteroids, improved peak forced expiratory volume in 1 second (FEV1) and reduced exacerbations in children younger than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results